8-K: Glaukos Reports Strong Q4, FY25 Sales; Reaffirms 2026 Outlook

Glaukos Corporation announced preliminary, unaudited net sales for Q4 and full year 2025, showing significant growth, and reaffirmed its 2026 revenue guidance.

Summary

• Preliminary, unaudited total net sales for the fourth quarter of 2025 are expected to be approximately $143 million, a 36% increase compared to the same period in 2024.
• Preliminary, unaudited total net sales for the full year of 2025 are expected to be approximately $507 million, a 32% increase compared to the full year of 2024.
• U.S. Glaucoma net sales for Q4 2025 were approximately $86 million, including iDose TR net sales of approximately $45 million.
• Full year 2025 U.S. Glaucoma net sales were approximately $299 million, with iDose TR contributing approximately $136 million.
• International Glaucoma net sales were approximately $33 million for Q4 2025 and $122 million for full year 2025.
• Corneal Health net sales were approximately $24 million for Q4 2025 and $86 million for full year 2025.
• The company ended the fourth quarter of 2025 with approximately $283 million in cash and cash equivalents, short-term investments, and restricted cash, and no debt.
• Glaukos reaffirms its 2026 net sales guidance range of $600 million to $620 million.

Sentiment

Score: 8

Explanation: The filing reports strong preliminary financial results for Q4 and full year 2025, with significant year-over-year growth. The company also reaffirmed its positive 2026 revenue guidance and highlighted a robust pipeline and strong cash position. This indicates strong operational performance and a confident outlook.

Positives

• Strong preliminary Q4 2025 net sales of $143 million, representing a 36% year-over-year increase.
• Robust preliminary full year 2025 net sales of $507 million, marking a 32% year-over-year increase.
• Significant contribution from iDose TR, with $45 million in Q4 2025 and $136 million for the full year 2025.
• Healthy cash position of approximately $283 million with no debt at the end of Q4 2025.
• Reaffirmation of strong 2026 net sales guidance of $600 million to $620 million, indicating confidence in continued growth.
• Successful advancement of a robust pipeline of novel, dropless platform technologies for chronic eye diseases.
• Commercial launch activities for Epioxa, the first and only FDA-approved epithelium-on treatment for keratoconus, expected in Q1 2026.

Risks

• Ability to successfully commercialize iDose TR and Epioxa therapies.
• Impact of general macroeconomic conditions, including foreign currency fluctuations and future health crises.
• Ability to generate sales of commercialized products and develop and commercialize additional products.
• Dependence on a limited number of third-party suppliers, some of which are single-source, for product components.
• The occurrence of a crippling accident, natural disaster, or other disruption at the primary facility, which may materially affect manufacturing capacity and operations.
• Securing or maintaining adequate coverage or reimbursement by government or third-party payors for products or procedures.
• Compliance with the requirements of participation in federal healthcare programs such as Medicare and Medicaid.
• Ability to properly train, and gain acceptance and trust from, ophthalmic surgeons in the use of products.
• Compliance with federal, state, and foreign laws and regulations for the approval and sale and marketing of products and manufacturing processes.
• The lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes.
• The risk of recalls or serious safety issues with products and the uncertainty of patient outcomes.
• Healthcare legislative or regulatory reform measures and changes in U.S. and international trade policies, including budgetary cuts, government shutdowns, and the imposition of tariffs.
• Ability to protect information systems against cyber threats and cybersecurity incidents, and to comply with state, federal, and foreign data privacy laws and regulations.
• Ability to protect, and the expense and time-consuming nature of protecting, intellectual property against third parties and competitors and the impact of any claims for infringement or misappropriation of third-party intellectual property rights and any related litigation.

Future Outlook

Glaukos reaffirms its 2026 net sales guidance range of $600 million to $620 million, indicating expected continued strong growth. The company anticipates sustaining its growth momentum through successful commercialization of existing products like iDose TR and the upcoming launch of Epioxa in Q1 2026, alongside the advancement of a robust pipeline of novel, dropless platform technologies for glaucoma, corneal disorders, and retinal diseases.

Management Comments

• Our record fourth quarter preliminary results cap off a highly successful year of global execution across our key commercial and development initiatives, leaving us well positioned to sustain our strong growth momentum in 2026 and beyond.
• We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

Industry Context

Glaukos is positioned as a pioneer in 'Interventional Glaucoma' and 'Interventional Keratoconus,' aiming to disrupt traditional treatment paradigms by offering dropless therapies and procedural interventions. This strategy addresses significant unmet needs, such as patient non-compliance with topical eye drops in glaucoma and the underdiagnosis/undertreatment of keratoconus. The company's focus on innovative solutions like iDose TR and Epioxa aligns with a broader industry trend towards more effective, patient-friendly, and compliance-independent treatments, particularly as ophthalmic surgeons seek to offset reductions in professional fees for cataract surgery.

Comparison to Industry Standards

• Glaukos positions itself as a "Best-in-Class Growth Company with Industry-Leading Pipeline," highlighting its 30% 2025 topline growth and 20%+ 10-year revenue CAGR.
• The company is an "Industry leader in micro-scale manufacturing with 20+ years experience."
• iDose TR is described as a "first-of-its-kind, long-duration, intracameral procedural pharmaceutical."
• Epioxa is highlighted as the "First and only FDA-approved epithelium-on treatment" for keratoconus.
• The company aims to lead the "IG Paradigm Shift," projecting that by 2035, US ophthalmologists could be performing as many IG procedures as cataract procedures, indicating a significant market transformation.
• The filing references Market Scope 2025 Glaucoma Surgical Device Report and Market Scope 2024 Glaucoma Pharmaceutical Report for market size estimates, suggesting a strong market position within these segments.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, reaffirmed growth guidance, and a robust product pipeline, suggesting potential for continued value creation.
• Patients: Positive impact through the development and commercialization of novel, dropless therapies for chronic eye diseases, aiming to improve outcomes, reduce treatment burden, and enhance quality of life.
• Ophthalmic Surgeons/Healthcare Providers: Positive impact by offering innovative procedural interventions and pharmaceutical solutions that address unmet clinical needs, potentially offsetting reductions in other procedure fees and enabling more proactive patient management.
• Employees: Positive impact from a growing company with expanding commercial and development initiatives, potentially leading to job security and growth opportunities.

Next Steps

• Glaukos will provide full financial and operating results for the fourth quarter and full year 2025 after the market close on Tuesday, February 17, 2026.
• Management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 17, 2026.
• Commercial launch activities for Epioxa are expected to commence in Q1 2026, with drug availability and establishment of site of care network.
• Accelerate marketing spend to support increased patient awareness and education for Epioxa.
• Expand the body of clinical evidence for Epioxa with peer-reviewed publications.
• Advance 6+ future iDose platform products, including iDose TRIO (NDA supplement filed December 2025, Phase 3b study commenced) and iDose TREX (advancing Phase 2b/3 clinical program).
• Continue Phase 2 clinical trials for 3rd Gen iLink for keratoconus.
• Advance Demodex blepharitis program into Phase 2 clinical stage with patient enrollment underway.
• Continue Phase 2a first-in-human clinical trial of IVT multi-kinase inhibitor program targeting AMD, DME, and RVO.

Key Dates

Recommendation

The filing demonstrates strong operational momentum with preliminary Q4 and full year 2025 net sales significantly increasing by 36% and 32% year-over-year, respectively. The reaffirmation of robust 2026 revenue guidance, coupled with a healthy cash position and no debt, signals management's confidence in sustained growth. The company's innovative pipeline, particularly with the commercial launch of Epioxa and the continued success of iDose TR, positions Glaukos as a leader in disrupting ophthalmic treatment paradigms. These factors suggest a strong growth trajectory and potential for continued shareholder value appreciation, making it an attractive investment.

Keywords

Glaukos, GKOS, ophthalmic, glaucoma, corneal disorders, retinal diseases, MIGS, iDose TR, Epioxa, net sales, revenue guidance, medical technology, pharmaceutical, keratoconus, eye care, biotech, medical devices